Intrauterine Growth Restriction Has an Impact on Amplitude-integrated EEG in Preterm Infants
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Intrauterine Growth Restriction
- Sponsor
- Medical University of Vienna
- Enrollment
- 156
- Locations
- 1
- Primary Endpoint
- aEEG score (including background pattern, occurrence of sleep-wake-cycling and presence of seizure activity)
- Last Updated
- 12 years ago
Overview
Brief Summary
Objective: The impact of intrauterine growth restriction (IUGR) on perinatal morbidity and long-term neurodevelopmental outcome has been published in numerous studies. Throughout this analysis, the influence of IUGR on the postnatal amplitude-integrated EEG (aEEG) in preterm infants below 30 weeks of gestation was assessed. The second concern was the correlation between the pattern of the aEEG in the first two weeks with neurodevelopmental outcome, comparing infants with and without IUGR.
Methods: Routinely assessed aEEG data of preterm infants with IUGR born below 30 weeks of gestation in the years 2005 until 2007 were analysed retrospectively according to the aEEG score (combining occurrence of sleep-wake-cycles, background activity and suspected seizure activity). Neurodevelopmental outcome was evaluated at 24 months using the Bayley Scales of Infant Development and standardized neurologic examination.
Investigators
Katrin Klebermass-Schrehof
MD
Medical University of Vienna
Eligibility Criteria
Inclusion Criteria
- •preterm infants below 30 weeks of gestation
Exclusion Criteria
- •congenital anomalies
- •severe asphyxia
Outcomes
Primary Outcomes
aEEG score (including background pattern, occurrence of sleep-wake-cycling and presence of seizure activity)
Time Frame: first 14 days of life
composite score background activity (BA), occurrence of sleep-wake-cycling (SWC) and presence of seizure activity (SA) meaning score 1= normal (normal BA, SWC yes, SA no) and score 2 and 3 = abnormal (2=abnormality in 1 category (BA, SWC or SA) and score 3= abnormality in 2 or 3 categories
Secondary Outcomes
- Neurodevelopmental outcome(24 months)